
Biotechnology
Innovations in cancer immunotherapy: Bi-specific T cell engagers
Bi-specific T cell engagers are poised to become key immunotherapy treatments due to simpler production and new safety advances.
The solution success story has been sent to your email address. If you do not receive it, you can download it by clicking the button below.
For more information, please visit CAS Custom Services℠.



